Response from the company:
Seeking approval for additional 10% issue capacity is pretty standard practice for companies that are eligible to seek this approval.In most cases, the companies do not have an intention to use the 10%, however, approval is sought to provide the company with the flexibility to use it if it becomes advantageous or necessary to do so.This is particularly advantageous when there are commercial reasons for a quick transaction, or where the delay in seeking shareholder approval may be detrimental to the success of a good transaction.
Based on this, I'm likely to vote against the increased placement capacity. I think the likelihood of seeking this capacity at a later date being detrimental to a a transaction is unlikely.
- Forums
- ASX - By Stock
- NC6
- Ann: Notice of Annual General Meeting/Proxy Form
NC6
nanollose limited
Add to My Watchlist
0.00%
!
6.5¢

Ann: Notice of Annual General Meeting/Proxy Form, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.82M |
Open | High | Low | Value | Volume |
6.4¢ | 6.8¢ | 6.0¢ | $28.76K | 454.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29999 | 6.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 32000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29999 | 0.065 |
1 | 4000 | 0.058 |
1 | 14000 | 0.053 |
1 | 37977 | 0.051 |
3 | 57273 | 0.050 |
Price($) | Vol. | No. |
---|---|---|
0.067 | 32000 | 1 |
0.068 | 9500 | 1 |
0.070 | 121000 | 1 |
0.077 | 200000 | 1 |
0.082 | 3400 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
NC6 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online